Medium impact
Hematopoietic Cell Transplantation for Aplastic Anemia and other Bone Marrow Failure Syndromes (CPB 0627, reviewed 2025-12-11)
Aetna·Effective Dec 11, 2025
HCPCS J9213 is officially defined as "Injection, interferon, alfa-2a, recombinant, 3 million units." HCPCS J9213 is referenced in 1 tracked payer policy change from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9213 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.